Loading company…
Suzhou-based biopharmaceutical firm offering small molecule drug research and development services.
Founded in 2017 and based in Suzhou, China, Sinovent is a biopharmaceutical company offering small molecule drug research and development. It has branch offices in Boston, Beijing, Shanghai and Sydney and 252 employees. The company raised CNY 1 billion in series C funding in August 2020 and CNY 700 million in series E funding in February 2024. Its pipeline includes BLI inhibitors, EZH2 inhibitors and hURAT1 inhibitors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in